TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Glioblastoma (GBM) is a fatal adult central nervous system (CNS) cancer with inevitable treatment resistance and recurrence.
• Standard treatments like radiation therapy (RT) and temozolomide (TMZ) efficacy is limited by acquired resistance.
• TRIB1 is a pseudokinase involved in protein degradation and signaling pathway activation.

Purpose of the Study:

• To investigate the role of TRIB1 in Glioblastoma (GBM) treatment resistance.
• To explore the molecular mechanisms by which TRIB1 influences GBM cell survival and proliferation.
• To assess TRIB1 as a potential therapeutic target for GBM.

Main Methods:

• Analysis of TRIB1 gene expression in GBM patient cohorts.
• In vitro studies using patient-derived GBM cell lines to assess apoptosis and signaling.
• Co-immunoprecipitation assays to determine protein-protein interactions.
• In vivo studies using mouse models of GBM.

Main Results:

• Increased TRIB1 gene expression correlated with worse overall survival in GBM patients.
• TRIB1 overexpression reduced radiation therapy/temozolomide-induced apoptosis in GBM cells.
• TRIB1 directly interacted with MEK, Akt, HDAC1, and p53, enhancing ERK and Akt activation.
• TRIB1 protein levels peaked during the G2/M cell cycle phase.
• TRIB1 overexpression in tumors led to decreased survival in mice.

Conclusions:

• TRIB1 promotes Glioblastoma (GBM) resistance to standard treatments (RT/TMZ) by activating cell proliferation and survival pathways.
• TRIB1's role in enhancing GBM cell survival and proliferation suggests it as a promising therapeutic target.
• Targeting TRIB1 may offer a novel strategy to overcome treatment resistance in Glioblastoma.